Felvizumab
Modify Date: 2024-04-06 19:07:45
Felvizumab structure
|
Common Name | Felvizumab | ||
|---|---|---|---|---|
| CAS Number | 167747-20-8 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of FelvizumabFelvizumab (SB 209763) is a humanized IgG1κ monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV[1][2]. |
| Name | Felvizumab |
|---|
| Description | Felvizumab (SB 209763) is a humanized IgG1κ monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV[1][2]. |
|---|---|
| Related Catalog | |
| Target |
EC50: 0.49 μg/mL (RSV Type A in microneutralization assay), 0.95 μg/mL (RSV Type A in fusion inhibition assay)[2] |
| In Vitro | Felvizumab (RSHZ19) (2 h or 4 h) 抑制 RSV A 型，微量中和试验中 EC50 为 0.49 ± 0.37 μg/mL，融合抑制试验中 EC50 为 0.95 ± 0.13 μg/mL[2]。 |
| In Vivo | Felvizumab (RSHZ19) (0.625-5.0 mg/kg; intramuscular injection; once) 在 RSV 感染大鼠模型中对 A 和 B 亚型 RSV 有效[2]。 Animal Model: Cotton rats, RSV infection model[2] Dosage: 0.625, 1.25, 2.5, and 5.0 mg/kg Administration: Intramuscular injection, 1 day before infection Result: Significantly reduced lung RSV titer. |
| References |
| No Any Chemical & Physical Properties |